The global market for therapeutics targeting IgG4-related disease is witnessing substantial development. Driven by an rising prevalence of these immunological conditions and the presence of novel treatment options, the market is poised for substantial opportunities in the foreseeable future. Key drivers stimulating this expansion include a rising r